较低危骨髓增生异常综合征患者的死因与超额死亡率:欧洲MDS登记处报告
该研究基于欧洲MDS登记处2008至2019年前瞻性纳入的2396例较低危MDS患者,评估死因与相对生存。900例死亡,中位总生存4.7年;最常见死因为急性髓系白血病/MDS(20.1%)、感染(17.8%)和心血管疾病(9.8%);5年总生存47.3%,5年相对生存59.6%。
要点
- 较低危MDS患者最常见死因为急性髓系白血病/MDS(20.1%)、感染(17.8%)和心血管疾病(9.8%)。
- 5年总生存47.3%,5年相对生存59.6%,提示多数患者死于基础MDS。
- 孤立del(5q)及病程中需红细胞输注的患者致死性心血管疾病风险更高。
核心结论
- MDS及其相关并发症在较低危MDS患者的结局中起关键作用。
研究设计与样本
- 前瞻性收集2008至2019年欧洲MDS登记处较低危MDS患者数据,共评估2396例,其中900例死亡。
主要发现
- 900例死亡患者中位总生存4.7年,中位随访3.5年。
- 最常见死因为急性髓系白血病/MDS(20.1%)、感染(17.8%)和心血管疾病(9.8%)。
- 孤立del(5q)及病程中需红细胞输注的患者致死性心血管疾病风险更高。
- 5年总生存47.3%,5年相对生存59.6%。
- 年龄>80岁患者及最低危患者更可能死于竞争性死因。
关键数值与推荐
- 最常见死因占比:急性髓系白血病/MDS 20.1%、感染17.8%、心血管疾病9.8%。
- 5年总生存47.3%,5年相对生存59.6%。
- 中位总生存4.7年,中位随访3.5年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.
引用
- Mądry K, Lis K, Fenaux P, et al. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry. Br J Haematol. 2022. PMID: 36335984. doi:10.1111/bjh.18542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。